|
1
|
Liu Y, Patel L, Mills GB, Lu KH, Sood AK,
Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, et al:
Clinical significance of CTNNB1 mutation and Wnt pathway activation
in endometrioid endometrial carcinoma. J Natl Cancer Inst.
106(106)2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Amant F, Moerman P, Neven P, Timmerman D,
Van Limbergen E and Vergote I: Endometrial cancer. Lancet.
366:491–505. 2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Baum M, Budzar AU, Cuzick J, Forbes J,
Houghton JH, Klijn JG and Sahmoud T: ATAC Trialists' Group.
Anastrozole alone or in combination with tamoxifen versus tamoxifen
alone for adjuvant treatment of postmenopausal women with early
breast cancer: First results of the ATAC randomised trial. Lancet.
359:2131–2139. 2002.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sasaki M, Dharia A, Oh BR, Tanaka Y,
Fujimoto S and Dahiya R: Progesterone receptor B gene inactivation
and CpG hypermethylation in human uterine endometrial cancer.
Cancer Res. 61:97–102. 2001.PubMed/NCBI
|
|
5
|
Daikoku T, Hirota Y, Tranguch S, Joshi AR,
DeMayo FJ, Lydon JP, Ellenson LH and Dey SK: Conditional loss of
uterine Pten unfailingly and rapidly induces endometrial cancer in
mice. Cancer Res. 68:5619–5627. 2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Colombo N, Preti E, Landoni F, Carinelli
S, Colombo A, Marini C and Sessa C: ESMO Guidelines Working Group.
Endometrial cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 24 (Suppl
6):vi33–38. 2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yoney A, Yildirim C, Isikli L and Unsal M:
Prognostic factors and treatment outcomes in patients with operated
endometrial cancer: Analysis of 674 patients at a single
institution. J BUON. 16:64–73. 2011.PubMed/NCBI
|
|
8
|
Su JL, Yang PC, Shih JY, Yang CY, Wei LH,
Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, et al: The
VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells.
Cancer Cell. 9:209–223. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Holst F, Werner HMJ, Mjøs S, Hoivik EA,
Kusonmano K, Wik E, Berg A, Birkeland E, Gibson WJ, Halle MK, et
al: PIK3CA amplification associates with aggressive phenotype but
not markers of AKT-mTOR signaling in endometrial carcinoma. Clin
Cancer Res. 25:334–345. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kodama J, Hasengaowa Kusumoto T, Seki N,
Matsuo T, Ojima Y, Nakamura K, Hongo A and Hiramatsu Y: Prognostic
significance of stromal versican expression in human endometrial
cancer. Ann Oncol. 18:269–274. 2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lin Q, Chen H, Zhang M, Xiong H and Jiang
Q: Knocking down FAM83B inhibits endometrial cancer cell
proliferation and metastasis by silencing the PI3K/AKT/mTOR
pathway. Biomed Pharmacother. 115(108939)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Alowayed N, Salker MS, Zeng N, Singh Y and
Lang F: LEFTY2 controls migration of human endometrial cancer cells
via focal adhesion kinase activity (FAK) and miRNA-200a. Cell
Physiol Biochem. 39:815–826. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nishita M, Enomoto M, Yamagata K and
Minami Y: Cell/tissue-tropic functions of Wnt5a signaling in normal
and cancer cells. Trends Cell Biol. 20:346–354. 2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wang J, Wen T, Li Z, Che X, Gong L, Yang
X, Zhang J, Tang H, He L, Qu X, et al: MicroRNA-1224 inhibits tumor
metastasis in intestinal-type gastric cancer by directly targeting
FAK. Front Oncol. 9(222)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Balsas P, Palomero J, Eguileor A,
Rodríguez ML, Vegliante MC, Planas-Rigol E, Sureda-Gómez M, Cid MC,
Campo E and Amador V: SOX11 promotes tumor protective
microenvironment interactions through CXCR4 and FAK regulation in
mantle cell lymphoma. Blood. 130:501–513. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Jiang H, Liu X, Knolhoff BL, Hegde S, Lee
KB, Jiang H, Fields RC, Pachter JA, Lim KH and DeNardo DG:
Development of resistance to FAK inhibition in pancreatic cancer is
linked to stromal depletion. Gut. 69:122–132. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yamaura T, Kasaoka T, Iijima N, Kimura M
and Hatakeyama S: Evaluation of therapeutic effects of FAK
inhibition in murine models of atherosclerosis. BMC Res Notes.
12(200)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Takeshita S, Fumoto T, Matsuoka K, Park
KA, Aburatani H, Kato S, Ito M and Ikeda K: Osteoclast-secreted
CTHRC1 in the coupling of bone resorption to formation. J Clin
Invest. 123:3914–3924. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Pyagay P, Heroult M, Wang Q, Lehnert W,
Belden J, Liaw L, Friesel RE and Lindner V: Collagen triple helix
repeat containing 1, a novel secreted protein in injured and
diseased arteries, inhibits collagen expression and promotes cell
migration. Circ Res. 96:261–268. 2005.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yang XM, You HY, Li Q, Ma H, Wang YH,
Zhang YL, Zhu L, Nie HZ, Qin WX, Zhang ZG, et al: CTHRC1 promotes
human colorectal cancer cell proliferation and invasiveness by
activating Wnt/PCP signaling. Int J Clin Exp Pathol. 8:12793–12801.
2015.PubMed/NCBI
|
|
21
|
He W, Zhang H, Wang Y, Zhou Y, Luo Y, Cui
Y, Jiang N, Jiang W, Wang H, Xu D, et al: CTHRC1 induces non-small
cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9.
BMC Cancer. 18(400)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tang L, Dai DL, Su M, Martinka M, Li G and
Zhou Y: Aberrant expression of collagen triple helix repeat
containing 1 in human solid cancers. Clin Cancer Res. 12:3716–3722.
2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Guo B, Yan H, Li L, Yin K, Ji F and Zhang
S: Collagen triple helix repeat containing 1 (CTHRC1) activates
Integrin β3/FAK signaling and promotes metastasis in ovarian
cancer. J Ovarian Res. 10(69)2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tang Z, Wang Y, Liu X and Liu Q: An
immunohistochemical study of CTHRC1, Vimentin, E-cadherin
expression in papillary thyroid carcinoma. Lin Chung Er Bi Yan Hou
Tou Jing Wai Ke Za Zhi. 32:595–598. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
25
|
Park EH, Kim S, Jo JY, Kim SJ, Hwang Y,
Kim JM, Song SY, Lee DK and Koh SS: Collagen triple helix repeat
containing-1 promotes pancreatic cancer progression by regulating
migration and adhesion of tumor cells. Carcinogenesis. 34:694–702.
2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lee J, Song J, Kwon ES, Jo S, Kang MK, Kim
YJ, Hwang Y, Bae H, Kang TH, Chang S, et al: CTHRC1 promotes
angiogenesis by recruiting Tie2-expressing monocytes to pancreatic
tumors. Exp Mol Med. 48(e261)2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Li LY, Yin KM, Bai YH, Zhang ZG, Di W and
Zhang S: CTHRC1 promotes M2-like macrophage recruitment and
myometrial invasion in endometrial carcinoma by integrin-Akt
signaling pathway. Clin Exp Metastasis. 36:351–363. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chandrashekar DS, Bashel B, Balasubramanya
SA, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BV and Varambally
S: UALCAN: A portal for facilitating tumor subgroup gene expression
and survival analyses. Neoplasia. 19:649–658. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Anaya J: OncoLnc: Linking TCGA survival
data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput Sci.
2(e67)2016.
|
|
30
|
Chen G, Wang D, Zhao X, Cao J, Zhao Y,
Wang F, Bai J, Luo D and Li L: miR-155-5p modulates malignant
behaviors of hepatocellular carcinoma by directly targeting CTHRC1
and indirectly regulating GSK-3β-involved Wnt/β-catenin signaling.
Cancer Cell Int. 17(118)2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Saed L, Varse F, Baradaran HR, Moradi Y,
Khateri S, Friberg E, Khazaei Z, Gharahjeh S, Tehrani S,
Sioofy-Khojine AB, et al: The effect of diabetes on the risk of
endometrial Cancer: An updated a systematic review and
meta-analysis. BMC Cancer. 19(527)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nomura H, Aoki D, Michimae H, Mizuno M,
Nakai H, Arai M, Sasagawa M, Ushijima K, Sugiyama T, Saito M, et
al: Japanese Gynecologic Oncology Group: Effect of taxane plus
platinum regimens vs doxorubicin plus cisplatin as adjuvant
chemotherapy for endometrial cancer at a high risk of progression:
A Randomized Clinical Trial. JAMA Oncol. 5:833–840. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Durmus T, LeClair RJ, Park KS, Terzic A,
Yoon JK and Lindner V: Expression analysis of the novel gene
collagen triple helix repeat containing-1 (Cthrc1). Gene Expr
Patterns. 6:935–940. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Lau EY, Lo J, Cheng BY, Ma MK, Lee JM, Ng
JK, Chai S, Lin CH, Tsang SY, Ma S, et al: Cancer-associated
fibroblasts regulate tumor-initiating cell plasticity in
hepatocellular carcinoma through c-Met/FRA1/HEY1 signaling. Cell
Rep. 15:1175–1189. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Tan F, Liu F, Liu H, Hu Y, Liu D and Li G:
CTHRC1 is associated with peritoneal carcinomatosis in colorectal
cancer: A new predictor for prognosis. Med Oncol.
30(473)2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ma MZ, Zhuang C, Yang XM, Zhang ZZ, Ma H,
Zhang WM, You H, Qin W, Gu J, Yang S, et al: CTHRC1 acts as a
prognostic factor and promotes invasiveness of gastrointestinal
stromal tumors by activating Wnt/PCP-Rho signaling. Neoplasia.
16:265–278, 278.e1-278.e13. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Berx G and van Roy F: Involvement of
members of the cadherin superfamily in cancer. Cold Spring Harb
Perspect Biol. 1(a003129)2009.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Cavallaro U and Christofori G: Cell
adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev
Cancer. 4:118–132. 2004.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wang P, Wang YC, Chen XY, Shen ZY, Cao H,
Zhang YJ, Yu J, Zhu JD, Lu YY and Fang JY: CTHRC1 is upregulated by
promoter demethylation and transforming growth factor-β1 and may be
associated with metastasis in human gastric cancer. Cancer Sci.
103:1327–1333. 2012.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Liu G, Sengupta PK, Jamal B, Yang HY,
Bouchie MP, Lindner V, Varelas X and Kukuruzinska MA:
N-glycosylation induces the CTHRC1 protein and drives oral cancer
cell migration. J Biol Chem. 288:20217–20227. 2013.PubMed/NCBI View Article : Google Scholar
|
